Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

Summary

This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2019-08-06

Primary completion

2022-02-02

Completion

2026-12-09

Publications

• Bilen MA, Vo BT, Liu Y, Greenwald R, Davarpanah AH, McGuire D, Shiradkar R, Li L, Nazha B, Brown JT, Williams S, Session W, Russler G, Caulfield S, Joshi SS, Narayan VM, Filson CP, Ogan K, Kucuk O, Carthon BC, Del Balzo L, Cohen A, Boyanton A, Prokhnevska N, Cardenas MA, Sobierajska E, Jansen CS, Patil DH, Nicaise E, Osunkoya AO, Kissick H, Master VA. Neoadjuvant cabozantinib restores CD8+ T cells in patients with locally advanced non-metastatic clear cell renal cell carcinoma: a phase 2 trial. Res Sq [Preprint]. 2024 Aug 8:rs.3.rs-4849400. doi: 10.21203/rs.3.rs-4849400/v1.

Drugs

Indications